Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and[…]
Peritoneal Mesothelioma
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal[…]
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST[…]
A Combination of Immunotherapy Drugs Could Help Mesothelioma Patients
Mesothelioma is an incurable cancer of the mesothelium resulting from asbestos exposure. Many clinical trials have been found to help patients but there is still no cure. People primarily have pleural mesothelioma where the linings of the lungs have cancer, but it can also affect the lining of the abdomen[…]
Halofuginone Could Soon be Used to Treat Mesothelioma
Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]
Upcoming Mesothelioma Events in 2020
If you are interested in learning more about mesothelioma, we have a curated list of different events coming up in 2020. If you live near or are able to travel to these events, they can help you and your loved ones understand the disease better. Mayo Clinic Radiation Oncology: Current[…]
Phase I Trial HIPEC With Nal-irinotecan
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Treatment outcomes for people with pleural or peritoneal mesothelioma are often poor. The drug LMB-100 can attack and kill cancer cells. The drug pembrolizumab helps the immune system fight cancer. Together, these drugs might help people with these cancers.
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis (COCOON)
Primary Outcome Measures Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire [ Time Frame: 90 days ]State anxiety reflects the current emotional state, which allows the patient’s nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety).[…]
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma In this study, patients in the experimental arm will be treated by 4 PIPAC (Cisplatine+Doxorubicine) alternating with 6 cycles of standard intravenous chemotherapy (Cisplatine+Pemetrexed).